| SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION |
| NOTE 10:- |
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION |
| |
|
December 31, |
|
| |
|
2014 |
|
|
2015 |
|
| |
|
|
|
|
|
|
| Director fees |
|
$ |
11 |
|
|
$ |
25 |
|
| Trade payables |
|
|
29 |
|
|
|
41 |
|
| Accrued expenses and other |
|
|
144 |
|
|
|
160 |
|
| |
|
|
|
|
|
|
|
|
| |
|
$ |
184 |
|
|
$ |
226 |
|
| |
b. |
Financial expenses, net |
| |
|
Year ended
December 31, |
|
| |
|
2013 |
|
|
2014 |
|
|
2015 |
|
| |
|
|
|
|
|
|
|
|
|
| Financial expenses: |
|
|
|
|
|
|
|
|
|
| Loss from change in fair value of investment in BioCancell and sale of BioCancell shares |
|
$ |
- |
|
|
$ |
(245 |
) |
|
$ |
(36 |
) |
| Other |
|
|
- |
|
|
|
(7 |
) |
|
|
(2 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
- |
|
|
$ |
(252 |
) |
|
$ |
(38 |
) |
| Financial income: |
|
|
|
|
|
|
|
|
|
|
|
|
| Income from change in fair value of investment in BioCancell and sale of BioCancell shares |
|
|
574 |
|
|
|
- |
|
|
|
- |
|
| Other |
|
|
5 |
|
|
|
12 |
|
|
|
9 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
579 |
|
|
|
12 |
|
|
|
9 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
$ |
579 |
|
|
$ |
(240 |
) |
|
$ |
(29 |
) |
|